tradingkey.logo

Sarepta falls on report of patient death in early-stage study

ReutersJul 18, 2025 9:42 AM

Shares of gene therapy maker Sarepta Therapeutics SRPT.O down 16.7% at $18.29 premarket

A patient enrolled in an early-stage study of one of co's gene therapies has died from acute liver failure, as per a Bloomberg report

U.S. FDA is already probing two earlier deaths due to acute liver failure in non-ambulatory Duchenne muscular dystrophy patients after receiving Sarepta's gene therapy, Elevidys

SRPT did not immediately respond to a Reuters' request for comment

As of last close, stock has slumped 81.9% so far this year

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI